Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis—Mechanisms, Evidence, and Therapeutic Potential
Pharmaceuticals · 19.07.2024 · 17 (7) · 963
DOI: 10.3390/ph17070963 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.07.2024. Verfasst von Ghada Khawaja und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, Beirut Arab University, Beirut 11-5020, Lebanon. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and damage. Oxidative stress plays a critical role in the onset and progression of RA, significantly contributing to the disease’s symptoms. The complex nature of RA and the role of oxidative stress make it particularly challenging to treat effectively. This article presents a comprehensive review of RA’s development, progression, and the emergence of novel treatments, introducing Galangin (GAL), a natural flavonoid compound sourced from various plants, as a promising candidate. The bioactive properties of GAL, including its anti-inflammatory, antioxidant, and immunomodulatory effects, are discussed in detail. The review elucidates GAL’s mechanisms of action, focusing on its interactions with key targets such as inflammatory cytokines (e.g., TNF-α, IL-6), enzymes (e.g., SOD, MMPs), and signaling pathways (e.g., NF-κB, MAPK), which impact inflammatory responses, immune cell activation, and joint damage. The review also addresses the lack of comprehensive understanding of potential treatment options for RA, particularly in relation to the role of GAL as a therapeutic candidate. It highlights the need for further research and clinical studies to ascertain the effectiveness of GAL in RA treatment and to elucidate its mechanisms of action. Overall, this review provides valuable insights into the potential of GAL as a therapeutic option for RA, shedding light on its multifaceted pharmacological properties and mechanisms of action, while suggesting avenues for future research and clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, Faculty of Science, Beirut Arab University, Beirut 11-5020, Lebanon.
- Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut 11-0236, Lebanon.
- Health Sciences Division, Abu Dhabi Women's College, Higher Colleges of Technology, Abu Dhabi P.O. Box 25026, United Arab Emirates.
ORCID-Profile: Ghada Khawaja, Aya Shoujaa
Zitieren
APA
Khawaja, G., El-Orfali, Y., Shoujaa, A., & Abou Najem, S. (2024). Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis—Mechanisms, Evidence, and Therapeutic Potential. Pharmaceuticals, 17(7), 963. https://doi.org/10.3390/ph17070963
Vancouver
Khawaja G, El-Orfali Y, Shoujaa A, Abou Najem S. Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis—Mechanisms, Evidence, and Therapeutic Potential. Pharmaceuticals. 2024;17(7):963. doi:10.3390/ph17070963
BibTeX
@article{Khawaja2024,
author = {Khawaja, Ghada and El-Orfali, Youmna and Shoujaa, Aya and Abou Najem, Sonia},
title = {Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis—Mechanisms, Evidence, and Therapeutic Potential},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {7},
pages = {963},
doi = {10.3390/ph17070963}
}
EUVIMED